Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Louie Ngar Yee reports acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• Louie Ngar Yee, a director of MAIA Biotechnology, Inc., filed a Form 4 on April 8, 2025, reporting a transaction.
• The transaction involved the acquisition of 26,304 stock options on April 4, 2025, at a price of $1.50.
• These options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date.
• Following the transaction, Louie Ngar Yee directly owns 26,304 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which can be seen as a positive sign of aligning management interests with shareholders, but doesn't inherently indicate strong positive or negative sentiment.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director can align the director's interests with those of the shareholders.

Key Dates

Keywords

MAIA Biotechnology, Stock Options, Form 4, Director, Acquisition, Equity Incentive Plan